Wong Chi Kin, Drucker Daniel J
Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.
Department of Medicine, University of Toronto, Ontario, Canada.
J Clin Invest. 2025 Nov 3;135(21). doi: 10.1172/JCI194751.
Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines. In this Review, we highlight current understanding of the direct and indirect antiinflammatory effects and mechanisms of GLP-1 medicines in both preclinical and clinical studies, covering emerging concepts, clinical relevance, and areas of uncertainty that require further investigation.
基于胰高血糖素样肽-1（GLP-1）的疗法可降低2型糖尿病和/或肥胖症患者患心血管疾病和慢性肾病的几率，目前正在进行的临床试验正在研究其对代谢性肝病、关节炎以及物质使用和神经退行性疾病患者的影响。GLP-1受体信号的急性和慢性激活还可通过体重减轻依赖性和非依赖性机制降低小鼠和人类的全身和组织炎症，这些作用可能有助于扩大GLP-1药物的临床益处范围。在本综述中，我们重点介绍了临床前和临床研究中对GLP-1药物直接和间接抗炎作用及机制的当前理解，涵盖了新兴概念、临床相关性以及需要进一步研究的不确定性领域。
